Mercodia and Attana Partner for Preclinical Bioanalysis
Mercodia and Attana are joining forces to develop next-generation solutions for preclinical drug development. By combining Mercodia’s bioanalytical expertise with Attana’s advanced biosensor technology, we aim to deliver more accurate and physiologically relevant insights in early-stage research.
Driving Innovation in Early-Stage Drug Development
The collaboration will begin in early 2026 and initially run for six months. During this period, Mercodia will use Attana’s Cell™250 instrument together with technical support from Attana. This step strengthens our position as a trusted partner in preclinical bioanalysis and supports faster, more reliable drug development.
“The collaboration with Attana is an important step to strengthen Mercodia’s bioanalytical expertise and broaden possibilities in the preclinical area using Attana’s advanced biosensor platform. This partnership aligns with Mercodia’s long-term strategy to support drug development in early phases and reflects our strong commitment to innovation, continuously evolving to deliver cutting-edge solutions for our customers,” says Jörgen Dahlström, CEO of Mercodia.
Combining Expertise and Technology
Attana views the collaboration as confirmation of the growing need for physiologically relevant bioanalysis in early drug development. A successful project could pave the way for further commercial opportunities and extended use of Attana’s technology within Mercodia’s CRO offering.
We look forward to working with Attana to create real value for our customers and drive innovation in life science.
→ Read the full press release
